CRIS Current Research Information System

CLISSA, CRISTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.916
EU - Europa 1.779
AS - Asia 1.656
AF - Africa 182
SA - Sud America 71
OC - Oceania 1
Totale 5.605
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.880
CN - Cina 538
SG - Singapore 534
GB - Regno Unito 450
IT - Italia 343
SE - Svezia 297
VN - Vietnam 258
DE - Germania 205
HK - Hong Kong 113
RU - Federazione Russa 89
IN - India 87
FR - Francia 59
IE - Irlanda 56
BR - Brasile 54
NL - Olanda 53
KR - Corea 52
TG - Togo 46
SC - Seychelles 42
GR - Grecia 41
ZA - Sudafrica 36
NG - Nigeria 34
CA - Canada 29
FI - Finlandia 29
UA - Ucraina 28
EE - Estonia 24
JO - Giordania 21
AT - Austria 20
CH - Svizzera 19
BE - Belgio 18
CI - Costa d'Avorio 18
BG - Bulgaria 17
HR - Croazia 14
IR - Iran 10
JP - Giappone 10
AR - Argentina 9
PL - Polonia 6
MX - Messico 5
PH - Filippine 5
BD - Bangladesh 4
IL - Israele 4
LT - Lituania 4
TR - Turchia 4
EC - Ecuador 3
ES - Italia 3
ID - Indonesia 3
LB - Libano 3
AZ - Azerbaigian 2
KG - Kirghizistan 2
MY - Malesia 2
TN - Tunisia 2
CO - Colombia 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EG - Egitto 1
GI - Gibilterra 1
GY - Guiana 1
IQ - Iraq 1
KE - Kenya 1
KH - Cambogia 1
LU - Lussemburgo 1
MA - Marocco 1
MK - Macedonia 1
MU - Mauritius 1
NZ - Nuova Zelanda 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
PY - Paraguay 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 5.605
Salva come PNG Salva come JPEG
Città #
Southend 418
Singapore 369
Ashburn 218
Chandler 197
Fairfield 180
Santa Clara 139
Hefei 138
Bologna 116
Hong Kong 113
Woodbridge 92
Houston 91
Beijing 89
Wilmington 89
Dong Ket 82
Seattle 80
Ann Arbor 78
Princeton 73
Cambridge 67
Dublin 56
Boardman 49
Lomé 46
Seoul 44
Westminster 40
Milan 38
Padova 37
Nanjing 36
Saint Petersburg 27
Abeokuta 26
New York 25
Medford 24
Helsinki 23
Ho Chi Minh City 22
Amman 21
Hanoi 21
Abidjan 18
Brussels 18
Jinan 18
Berlin 17
Los Angeles 17
Sofia 17
Buffalo 16
Changsha 16
Shenyang 16
Bern 15
Frankfurt am Main 15
Turin 15
Jiaxing 14
Redwood City 14
Vienna 14
Bengaluru 12
Hebei 12
Munich 12
Nanchang 12
Redondo Beach 12
Bremen 10
Tappahannock 10
Dallas 9
Florence 9
Montreal 9
Tianjin 9
Amsterdam 8
Dearborn 8
Grafing 8
Haikou 8
Norwalk 8
San Diego 8
Toronto 8
Valsamoggia 8
Athens 7
Falkenstein 7
Shanghai 7
Tokyo 7
Zhengzhou 7
Falls Church 6
Hangzhou 6
Jacksonville 6
Mahé 6
North York 6
Tongling 6
Turku 6
Bühl 5
Davao City 5
Rome 5
São Paulo 5
Wuhan 5
Yubileyny 5
Andover 4
Fuzhou 4
Guangzhou 4
Istanbul 4
London 4
Mülheim 4
Orem 4
Riolo Terme 4
Taizhou 4
Brooklyn 3
Busto Arsizio 3
Faenza 3
Haiphong 3
Jakarta 3
Totale 3.742
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 315
Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes 257
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 240
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 238
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 202
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 201
Molecular Characterization of High-Risk MDS Patients Treated with Azacitidine and Lenalidomide: Role of Inositide-Dependent Signalling, Mutations and Microrna 196
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 194
Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy 191
An increased expression of PI-PLCβ1 is associated with myeloid differentiation and a longer response to azacitidine in myelodysplastic syndromes 176
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 174
Azacitidine in Myelodysplastic Syndromes: Multicenter Retrospective Study of 34 Long-Responder Patients 174
Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies 173
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 163
Epigenetic regulation of nuclear inositide signalling in high-risk MDS patients 158
CLINICAL OUTCOME OF T-ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA (T-ALL/TLBL): THE BOLOGNA EXPERIENCE 157
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 154
DIFFERENTIAL EFFECT OF LENALIDOMIDE ON INDUCTION OF INOSITIDE-DEPENDENT ERYTHROPOIESIS AND CELL CYCLE IN MYELODYSPLASTIC SYNDROMES 153
Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients 153
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 146
Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes 145
Nuclear inositide signaling in myelodysplastic syndromes. 139
Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment 136
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. 126
Nelarabine is safe and effective in adult relapsed or refractory T cellacute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LBL): The Bologna experience 125
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 124
Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients. 118
Nuclear PI-PLC β1 and Myelodysplastic Syndromes: From Bench to Clinics 115
Nelarabine Is Safe and Effective In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL): The Bologna Experience 113
NELARABINE FRONT-LINE THERAPY FOR ADULT T-LYMPHOBLASTIC LEUKAEMIA/LYMPHOMA (T-LBL/ALL): PRELIMINARY RESULTS OF BOLOGNA EXPERIENCE 104
null 103
RASGRP1/APTX ratio is a strong biomarker which predicts response to therapy with Tipifarnib plus Bortezomib in elderly patients with Acute Myeloid Leukemia (AML) 102
NELARABINE IS SAFE AND EFFECTIVE IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) AND LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 102
[Molecular biology in myelodysplastic syndromes and acute myeloid leukemias "smoldering"] 97
PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment. 94
Nuclear translocation of PKC-alpha is associated with cell cycle arrest and erythroid differentiation in myelodysplastic syndromes (MDSs) 73
null 71
Totale 5.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.907
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021361 0 0 0 0 0 14 16 35 50 25 9 212
2021/2022778 84 11 52 86 78 48 19 38 39 72 120 131
2022/2023881 72 127 43 114 73 65 31 92 144 9 73 38
2023/2024296 7 41 20 30 40 62 9 18 20 18 16 15
2024/2025832 36 69 71 49 173 50 53 31 3 54 52 191
2025/20261.043 193 211 170 139 246 84 0 0 0 0 0 0
Totale 5.702